Summary of Weili Medical Conference Call Company Overview - **Company**: Weili Medical - **Date**: May 7, 2025 Key Points Industry and Company Developments - Weili Medical is enhancing its product competitiveness and gross margin through continuous product system upgrades, including new products in anesthesia and catheterization, such as visual double-lumen intubation and hydrophilic coated super-smooth catheters [2][3] - The company has implemented a marketing reform by integrating market channels and sales personnel, resulting in a reduction of marketing personnel from 373 to 308, while improving team efficiency. The marketing expense ratio decreased from 12.8% in 2021 to 10.5% in 2024, enhancing profitability [2][5] - To ensure supply chain stability, Weili Medical is expanding production in Zhaoqing and Mexico, increasing capacity and automation levels, mitigating geopolitical risks, and planning a second overseas production base in Southeast Asia [2][6] Financial Performance - The company's performance over the past two years was impacted by a decline in exports (due to inventory destocking by major North American clients) and a decrease in domestic sales (due to anti-corruption measures in domestic hospitals). However, domestic sales began to recover in Q2 2024, which is expected to improve industry operational order and competitive landscape in the long term [2][7] - Weili Medical's overseas business is gradually recovering, with a significant increase in gross margin attributed to the upgrade of export product systems and an increase in high-end product collaborations. Overseas gross margin improved from 27.1% in 2021 to 35.6% in 2024 [2][10] Product Development and R&D - The company has made significant progress in product upgrades and R&D investments, with R&D expenses increasing from 42 million yuan in 2019 to 111 million yuan in 2024, and the R&D expense ratio rising from 4.3% to 7.4%. The number of R&D personnel grew from 313 to 425, increasing their proportion from 13% to 15.4% [3] - New high-margin products have been introduced in the anesthesia and catheterization fields, contributing to improved overall gross margin and profitability [3][11] Domestic Market Dynamics - Despite a slowdown in growth due to anti-corruption measures, the gross margin remains stable, with profit growth significantly outpacing revenue growth. High-margin new products are expected to drive domestic revenue and gross margin [4][11] - The company has a low market share in several product categories, indicating substantial room for growth. For example, the gross margin for visual double-lumen intubation is 79%, while the overall gross margin for the anesthesia line is 57% [11][12] Overseas Market Strategy - Weili Medical is diversifying its overseas customer base to reduce revenue concentration risks. As of the first three quarters of 2024, North America accounted for 34% of export revenue, Europe 29%, Asia 13%, and South America 8% [4][14] - The company is transitioning from OEM to self-branded sales, with the proportion of self-branded sales increasing from 14% in 2022 to 19% in 2024 [13] Future Outlook - The outlook for Weili Medical remains optimistic, with strong core growth drivers including ongoing product upgrades, increased R&D investment, an efficient marketing team, and stable manufacturing layouts. The gradual reduction of anti-corruption impacts and the normalization of domestic operations are expected to support continued growth [8] - Profit forecasts for the company indicate a steady growth trajectory, with expected net profits of 260 million yuan, 320 million yuan, and 390 million yuan for 2025 to 2027, representing year-on-year growth rates of 20.3%, 20.8%, and 21.9% respectively [15]

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 产品体系升级是核心成长动力，研发、销售、制造全方位配套。 公司此前被看做传统低值耗材公司，但近年来产品升级已逐渐成为其核心成长动力，从 研发、营销到制造端，公司已为其产品体系升级的长期业务发展趋势做好全面配套。 过去两年受到外部因素干扰，产品升级成效未能完全体 现 | 一、 产品体系升级是核心成长动力,研发、销售、制造全方位配套 . | | --- | | (一) 研发:持续提高投入,产品管线不断升级 | | （二） 营销:国内营销改革成果显著,海外推进大客户定制化项目和本土化策略6 | | (三) 制造:国内肇庆建厂扩产,海外墨西哥建厂保障供应链稳定………………………………………………………… 7 | | 二、 过去两年受到外部因素干扰,产品升级成效未能完全体现 | | (一) 23年外销受到海外大客户去库存的影响 | | ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company is transitioning from low-cost to high-cost products, initiating a new phase of high growth despite facing external challenges in recent years [10][11]. - The overall profitability has significantly improved, with gross margins increasing from 43.2% in 2022 to 44.5% in 2024, despite revenue growth being impacted by external factors [2][41]. - Future growth is expected to be driven by the introduction of high-margin new products and the gradual reduction of the impact from anti-corruption measures in the domestic market [46][48]. Summary by Sections Product System Upgrade as Core Growth Driver - The company has focused on upgrading its product system across research, sales, and manufacturing, transitioning from a traditional low-value consumables company to a more innovative entity [15][16]. - R&D investment has increased from 0.42 billion in 2019 to 1.11 billion in 2024, with the R&D expense ratio rising from 4.3% to 7.4% [16][18]. Impact of External Factors on Performance - In 2023, external factors such as inventory destocking by overseas clients led to a decline in export revenue, which fell to 2.64 billion, a year-on-year decrease of 18% [1][31]. - Domestic sales were also affected by anti-corruption measures, resulting in a 15% year-on-year decline in the second half of 2023 [1][34]. Future Outlook and Margin Improvement - The report anticipates that the impact of anti-corruption will diminish, allowing for the accelerated introduction of high-margin new products, which will boost domestic sales and margins [46][48]. - The company is also expanding its overseas operations to mitigate geopolitical risks, with plans for new manufacturing facilities in Mexico and Southeast Asia [49][50]. Financial Forecast and Valuation - The projected total revenue for 2024 is 1.509 billion, with a year-on-year growth rate of 8.8%, and net profit is expected to reach 219 million, reflecting a 14% increase [4][12]. - The target price for the company's stock is set at 16 yuan, with a current price of 11.59 yuan, indicating significant upside potential [4][9].